Genetic characteristics of gastric-type mucinous carcinoma of the uterine cervix.
Adenocarcinoma
/ chemistry
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ analysis
DNA Mutational Analysis
Female
Genetic Predisposition to Disease
High-Throughput Nucleotide Sequencing
Humans
Immunohistochemistry
Middle Aged
Mutation
Neoplasms, Cystic, Mucinous, and Serous
/ chemistry
Phenotype
Uterine Cervical Neoplasms
/ chemistry
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
11
03
2020
accepted:
23
06
2020
revised:
18
06
2020
pubmed:
10
7
2020
medline:
4
11
2021
entrez:
10
7
2020
Statut:
ppublish
Résumé
Gastric-type mucinous carcinoma (GAS) is a recently established variant of endocervical mucinous adenocarcinoma that is characterized as being unrelated to HPV and having aggressive behavior and chemoresistance. GAS has a distinct morphology resembling nonneoplastic gastric glands or pancreaticobiliary adenocarcinoma, and their possible genetic similarity has been posed. In this study, next-generation sequencing was performed in 21 GAS cases using a customized panel including 94 cancer-associated genes. A total of 54 nonsynonymous somatic mutations were detected with an average mutation rate of 2.6 per lesion (range: 0-9). The most frequently mutated gene was TP53 (11/21, 52.4%), followed by STK11, HLA-B, PTPRS (4/21, 19.0%), FGFR4 (3/21, 14.3%), GNAS, BRCA2, ELF3, ERBB3, KMT2D, SLX4 (2/21, 9.5%), CDH1, EPCAM, KRAS, MLH1, RNF43, SNAI1, TWIST1, ZEB1, ZEB2, and so on (1/21, 4.8%). The mutated genes were mostly involved in signal transduction, DNA damage repair, and epithelial-mesenchymal transition (EMT). Correlation of TP53 mutation and p53 protein expression demonstrated that 31.3% with abnormal p53 expression harbored wild-type TP53. Compared to genetic features of gastric and pancreaticobiliary adenocarcinoma, TP53 mutations were frequent in both GAS and gastrointestinal adenocarcinoma. While KMT2D, ERBB3, and RNF43 mutations were shared between GAS and gastric adenocarcinoma, highly mutated genes in pancreatic ductal adenocarcinoma such as KRAS, SMAD4, and CDKN2A were rarely mutated in GAS. Of frequently mutated genes in cholangiocarcinoma, BAP1 and HLA-B were identified in GAS. Frequent EMT-related gene mutations suggested a possible role of EMT-related pathways in tumor dissemination and chemoresistance of GAS. In addition, GAS shared some genetic features with gastrointestinal adenocarcinoma. These findings provide a clue in understanding the biological basis of GAS.
Identifiants
pubmed: 32641744
doi: 10.1038/s41379-020-0614-0
pii: S0893-3952(22)00663-9
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
637-646Références
Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States—a 24-year population-based study. Gynecol Oncol. 2000;78:97–105.
pubmed: 10926787
Bray F, Carstensen B, Møller H, Zappa M, Žakelj MP, Lawrence G, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomark Prev. 2005;14:2191–9.
Stolnicu S, Barsan I, Hoang L, Patel P, Terinte C, Pesci A, et al. International endocervical adenocarcinoma criteria and classification (IECC): a new pathogenetic classification for invasive adenocarcinomas of the endocervix. Am J Surg Pathol. 2018;42:214–26.
pubmed: 29135516
pmcid: 5762258
Nishio S, Mikami Y, Tokunaga H, Yaegashi N, Satoh T, Saito M, et al. Analysis of gastric-type mucinous carcinoma of the uterine cervix—an aggressive tumor with a poor prognosis: a multi-institutional study. Gynecol Oncol. 2019;153:13–9.
pubmed: 30709650
Park KJ, Kiyokawa T, Soslow RA, Lamb CA, Oliva E, Zivanovic O, et al. Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus. Am J Surg Pathol. 2011;35:633–46.
pubmed: 21490443
Kusanagi Y, Kojima A, Mikami Y, Kiyokawa T, Sudo T, Yamaguchi S, et al. Absence of high-risk Human Papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype. Am J Pathol. 2010;177:2169–75.
pubmed: 20829441
pmcid: 2966776
Pirog EC, Lloveras B, Molijn A, Tous S, Guimerà N, Alejo M, et al. HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. Mod Pathol. 2014;27:1559–67.
pubmed: 24762548
Kojima A, Shimada M, Mikami Y, Nagao S, Takeshima N, Sugiyama T, et al. Chemoresistance of gastric-type mucinous carcinoma of the uterine cervix: a study of the sankai gynecology study group. Int J Gynecol Cancer. 2018;28:99–106.
pubmed: 29206664
Kojima A, Mikami Y, Sudo T, Yamaguchi S, Kusanagi Y, Ito M, et al. Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix. Am J Surg Pathol. 2007;31:664–72.
pubmed: 17460448
Pirog EC, Park KJ, Kiyokawa T, Zhang X, Chen W, Jenkins D, et al. Gastric-type adenocarcinoma of the cervix: tumor with wide range of histologic appearances. Adv Anat Pathol. 2019;26:1–12.
pubmed: 30234500
Ishii K, Katsuyama T, Ota H, Watanabe T, Matsuyama I, Tsuchiya S, et al. Cytologic and cytochemical features of adenoma malignum of the uterine cervix. Cancer Cytopathol. 1999;87:245–53.
pubmed: 10536348
Utsugi K, Hirai Y, Takeshima N, Akiyama F, Sakurai S, Hasumi K. Utility of the monoclonal antibody HIK1083 in the diagnosis of adenoma malignum of the uterine cervix. Gynecol Oncol. 1999;75:345–8.
pubmed: 10600287
Garg S, Nagaria TS, Clarke B, Freedman O, Khan Z, Schwock J, et al. Molecular characterization of gastric-type endocervical adenocarcinoma using next-generation sequencing. Mod Pathol. 2019;32:1823–33.
pubmed: 31308508
Carleton C, Hoang L, Sah S, Kiyokawa T, Karamurzin YS, Talia KL, et al. A detailed immunohistochemical analysis of a large series of cervical and vaginal gastric-type adenocarcinomas. Am J Surg Pathol. 2016;40:636–44.
pubmed: 26685087
pmcid: 5564425
Burk RD, Chen Z, Saller C, Tarvin K, Carvalho AL, Scapulatempo-Neto C, et al. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378–84.
Murali R, Filippo MD, Weigelt BWPK. Genomic characterization of gastric-type endocervical adenocarcinomas (abstract). Mod Pathol. 2016;31:1185.
Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: International Agency for Research on Cancer; 2014. p. 307.
Köbel M, Reuss A, Du Bois A, Kommoss S, Kommoss F, Gao D, et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol. 2010;222:191–8.
pubmed: 20629008
Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih IM, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 2011;24:1248–53.
pubmed: 21552211
An H, Song KS, Nimse SB, Kim J, Nguyen VT, Ta VT, et al. HPV 9G DNA chip: 100% clinical sensitivity and specificity. J Clin Microbiol. 2012;50:562–8.
pubmed: 22170909
pmcid: 3295105
Raphael BJ, Hruban RH, Aguirre AJ, Moffitt RA, Yeh JJ, Stewart C, et al. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 2017;32:185–203.
Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.
pmcid: 4170219
Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, et al. Landscape of genomic alterations in cervical carcinomas. Nature. 2014;506:371–5.
pubmed: 24390348
Hodgson A, Park KJ. Cervical adenocarcinomas: a heterogeneous group of tumors with variable etiologies and clinical outcomes. Arch Pathol Lab Med. 2019;143:34–46.
pubmed: 30785336
Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 2017;18:2780–94.
pubmed: 28297679
pmcid: 5493145
Getz G, Gabriel SB, Cibulskis K, Lander E, Sivachenko A, Sougnez C, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73.
Goldenring JR. Pyloric metaplasia, pseudopyloric metaplasia, ulcer-associated cell lineage and spasmolytic polypeptide-expressing metaplasia: reparative lineages in the gastrointestinal mucosa. J Pathol. 2018;245:132–7.
pubmed: 29508389
pmcid: 6026529
Yuan S, Norgard RJ, Stanger BZ. Cellular plasticity in cancer. Cancer Discov. 2019;9:837–51.
pubmed: 30992279
pmcid: 6606363
Mikami Y, Kiyokawa T, Hata S, Fujiwara K, Moriya T, Sasano H, et al. Gastrointestinal immunophenotype in adenocarcinomas of the uterine cervix and related glandular lesions: a possible link between lobular endocervical glandular hyperplasia/pyloric gland metaplasia and “adenoma malignum”. Mod Pathol. 2004;17:962–72.
pubmed: 15143335
Shekhani MT, Jayanthy AS, Maddodi N, Setaluri V. Cancer stem cells and tumor transdifferentiation: implications for novel therapeutic strategies. Am J Stem Cells. 2013;2:52–61.
pubmed: 23671816
pmcid: 3636725
Zhao M, Kong L, Liu Y, Qu H. DbEMT: an epithelial-mesenchymal transition associated gene resource. Sci Rep. 2015;5:1–14.
Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–90.
pubmed: 19945376
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–15.
pubmed: 18485877
pmcid: 2728032
Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741–51.
pubmed: 20531305
pmcid: 3176718
Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ. 2006;13:941–50.
pubmed: 16601750
Wang YC, Lin RK, Tan YH, Chen JT, Chen CY, Wang YC. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer. J Clin Oncol. 2005;23:154–64.
pubmed: 15625370
Lim SO, Park YM, Kim HS, Quan X, Yoo JE, Park YN, et al. Notch1 differentially regulates oncogenesis by wildtype p53 overexpression and p53 mutation in grade III hepatocellular carcinoma. Hepatology. 2011;53:1352–62.
pubmed: 21480340
Guillou L, Estreicher A, Chaubert P, Hurlimann J, Kurt AM, Metthez G, et al. Germ cell tumors of the testis overexpress wild-type p53. Am J Pathol. 1996;149:1221–8.
pubmed: 8863671
pmcid: 1865176
Rubio MP, Von Deimling A, Yandell DW, Wiestler OD, Gusella JF, Louis DN. Accumulation of wild type p53 protein in human astrocytomas. Cancer Res. 1993;53:3465–7.
pubmed: 8339248
Jimenez GS, Khan SH, Stommel JM, Wahl GM. p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene. 1999;18:7656–65.
pubmed: 10618705
Ge S, Li B, Li Y, Li Z, Liu Z, Chen Z, et al. Genomic alterations in advanced gastric cancer endoscopic biopsy samples using targeted next-generation sequencing. Am J Cancer Res. 2017;7:1540–53.
pubmed: 28744403
pmcid: 5523034
Misumi K, Hayashi A, Shibahara J, Arita J, Sakamoto Y, Hasegawa K, et al. Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss. Histopathology. 2017;70:766–74.
pubmed: 27864835
Andrici J, Goeppert B, Sioson L, Clarkson A, Renner M, Stenzinger A, et al. Loss of BAP1 expression occurs frequently in intrahepatic cholangiocarcinoma. Medicine. 2016;95:1–8.